Annals of Internal Medicine Cover Letter: A Clinical-Decision Template

Paragraph 1: identify the study and answer. State the article type, population, design, comparison, outcome, and main result.

Paragraph 2: explain the internal-medicine consequence. Name the clinical, diagnostic, therapeutic, prognostic, policy, or evidence-method decision the result informs.

Paragraph 3: show why the inference is credible. Point to the prespecified endpoint, allocation or adjustment strategy, validation, sensitivity analysis, follow-up, and uncertainty that carry the conclusion. Name the most important boundary.

Paragraph 4: complete the record. Confirm exclusive consideration and author approval. Disclose registration, prior dissemination, related manuscripts, funding, conflicts, ethics, patient consent, data access, and any current requirement that applies.

Weak: “Our large real-world study proves that the intervention should become standard of care.”

Stronger: “In a target-trial emulation across two health systems, treatment initiation was associated with fewer 30-day admissions than the active comparator; negative-control and sensitivity analyses reduced, but did not eliminate, residual-confounding concerns.”

The stronger sentence distinguishes association from proof, names the comparison and outcome, and makes the uncertainty inspectable.

Put the letter beside the protocol or analysis plan, registry entry, manuscript, reporting checklist, data statement, conflicts form, and portal answers. Patient counts, enrollment dates, primary outcomes, analysis populations, effect estimates, funding, and data conditions should agree.

For trials, state the registration and primary analysis faithfully. For observational work, avoid causal verbs unless the design and analysis support them. For diagnostic and prediction studies, distinguish discrimination, calibration, clinical utility, and external validation. For systematic reviews, make the question, protocol, search date, certainty method, and update boundary visible.

Use the Annals of Internal Medicine submission guide for the full package. Compare JAMA Internal Medicine, The BMJ, or a specialty journal when the readership and evidence consequence are narrower or differently shaped.

Practice change beyond design. A single observational association becomes a treatment recommendation.

Broad readership asserted, not shown. The letter says “relevant to all clinicians” without naming a decision that travels across internal medicine.

Primary outcome drift. The letter leads with a favorable secondary or subgroup result that the abstract treats as exploratory.

Registry mismatch. Enrollment, outcomes, or analysis timing differ between the letter, registry, and manuscript.

Data-access overpromise. The letter says data are available while the data statement imposes unmentioned restrictions.

In our review of clinical manuscripts, the most persuasive letter is rarely the one with the strongest adjectives. It is the one that lets an editor trace a patient or policy decision through the design, comparison, endpoint, effect estimate, uncertainty, and limitations. Write those elements in a single row before drafting. If one is missing, the clinical consequence is probably not ready to lead the letter.

We trace every clinical verb back to the design. Next, test the verb. Randomized evidence, observational associations, diagnostic accuracy, prediction, quality improvement, and methodological studies support different kinds of inference. Replace “improves,” “prevents,” or “changes practice” when the design supports only association, estimation, feasibility, or a hypothesis for the next study. The named failure pattern is design-consequence inflation: the letter claims a care effect that the study can only associate, estimate, or motivate. This is not timid writing; it makes the genuine contribution easier to trust.

Use the official ACP author information to reach the current submission system. The journal guide index can help compare adjacent clinical routes, but the cover letter should defend only the journal the present evidence actually fits.

Give the completed letter to a reader who has not seen the study and ask four questions: Who was studied? What was compared? Which outcome changed, by how much, and with what uncertainty? What clinical decision could the result inform? If any answer depends on opening the abstract, the letter has not yet done its routing job.

Next, compare every denominator. Enrollment, exclusions, analysis populations, missing outcomes, follow-up, and adverse-event counts should not silently change across the registry, flow diagram, abstract, tables, letter, and portal. Where the study has more than one analysis population, name the one carrying the cover-letter estimate. Where an effect is adjusted, say so rather than letting it read like an unqualified raw difference.

End with a boundary check. Replace universal language when the study is limited by setting, selection, duration, endpoint ascertainment, residual confounding, calibration, or external validation. A candid limitation does not sabotage the submission; it tells the editor that the authors understand what the study can support. The most useful final letter gives Annals a clinically consequential result and a transparent reason to trust its scope, without turning uncertainty into either apology or overclaim.